CV Protection in the EMPA-REG OUTCOME Trial: A “Thrifty Substrate” Hypothesis
The DOI matches its Crossref record; 77 of the 77 references it cites were found in a registry or an index.
Abstract
The striking and unexpected relative risk reductions in cardiovascular (CV) mortality (38%), hospitalization for heart failure (35%), and death from any cause (32%) observed in the EMPA-REG OUTCOME trial using an inhibitor of sodium–glucose cotransporter 2 (SGLT2) in patients with type 2 diabetes and high CV risk have raised the possibility that mechanisms other than those observed in the trial—modest improvement in glycemic control, small decrease in body weight, and persistent reductions in blood pressure and uric acid level—may be at play. We hypothesize that under conditions of mild, persistent hyperketonemia, such as those that prevail during treatment with SGLT2 inhibitors, β-hydroxybutyrate is freely taken up by the heart (among other organs) and oxidized in preference to fatty acids. This fuel selection improves the transduction of oxygen consumption into work efficiency at the mitochondrial level. In addition, the hemoconcentration that typically follows SGLT2 inhibition enhances oxygen release to the tissues, thereby establishing a powerful synergy with the metabolic substrate shift. These mechanisms would cooperate with other SGLT2 inhibition–induced changes (chiefly, enhanced diuresis and reduced blood pressure) to achieve the degree of cardioprotection revealed in the EMPA-REG OUTCOME trial. This hypothesis opens up new lines of investigation into the pathogenesis and treatment of diabetic and nondiabetic heart disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Böhm, M., Burri, H., Butler, J., Čelutkienė, J., Chioncel, O., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab670 · Cited by 19,442
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
How mitochondria produce reactive oxygen species
Murphy, M. P. (2009) · Biochemical Journal · doi:10.1042/bj20081386 · Cited by 8,207 · cited 1×
“Furthermore, a persistently elevated rate of FFA oxidation generates reactive oxygen species in excess of scavenging capacity (42); the resulting oxidative stress contributes to mitochondrial damage in a range of pathologies (43).”
BackgroundESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012
Authors/Task Force Members, McMurray, J. J. V., Adamopoulos, S., Anker, S. D., Auricchio, A., Böhm, M., Dickstein, K., Falk, V., Filippatos, G., Fonseca, C., et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs104 · Cited by 6,879
Eplerenone in patients with systolic heart failure and mild symptoms
Zannad, F., McMurray, J. J. V., Krum, H., van Veldhuisen, D. J., Swedberg, K., Shi, H., Vincent, J., Pocock, S. J., & Pitt, B. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009492 · Cited by 3,111
Ischaemic accumulation of succinate controls reperfusion injury through mitochondrial ROS
Chouchani, E. T., Pell, V. R., Gaude, E., Aksentijević, D., Sundier, S. Y., Robb, E. L., Logan, A., Nadtochiy, S. M., Ord, E. N. J., Smith, A. C., et al. (2014) · Nature · doi:10.1038/nature13909 · Cited by 2,907 · cited 1×
“perfusion injury (53)dconverge on insufficient mitochondrial energy output and contractile failure as the basic mechanism.”
BackgroundESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012
Authors/Task Force Members, McMurray, J. J. V., Adamopoulos, S., Anker, S. D., Auricchio, A., Böhm, M., Dickstein, K., Falk, V., Filippatos, G., Fonseca, C., et al. (2012) · European Journal of Heart Failure · doi:10.1093/eurjhf/hfs105 · Cited by 2,644
The Failing Heart — An Engine Out of Fuel
Neubauer, S. (2007) · New England Journal of Medicine · doi:10.1056/nejmra063052 · Cited by 2,417
Myocardial Fatty Acid Metabolism in Health and Disease
Lopaschuk, G. D., Ussher, J. R., Folmes, C. D. L., Jaswal, J. S., & Stanley, W. C. (2010) · Physiological Reviews · doi:10.1152/physrev.00015.2009 · Cited by 2,179
Myocardial Substrate Metabolism in the Normal and Failing Heart
Stanley, W. C., Recchia, F. A., & Lopaschuk, G. D. (2005) · Physiological Reviews · doi:10.1152/physrev.00006.2004 · Cited by 2,048 · cited 1×
“and functional manifestation (reduced or preserved ejection fraction) (51).”
Background
Cited by
Items 601–700 of 1,000
Connelly, K. A., Wu, X., Visram, A., Friedberg, M. K., Batchu, S. N., Yerra, V. G., Thai, K., Nghiem, L., Zhang, Y., Kabir, G., et al. (2022) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-022-07377-1 · Cited by 11
“Other mechanisms to account for the cardioprotective properties of SGLT2i involve improved myocardial energetics because of altered substrate delivery [27].”
Nagendra, L., Dutta, D., Girijashankar, H. B., Khandelwal, D., Lathia, T., & Sharma, M. (2024) · Annals of Pediatric Endocrinology & Metabolism · doi:10.6065/apem.2346162.081 · Cited by 8
“29) Patients with T1DM with metabolic syndrome on SGLT2i are at higher risk of euglycemic ketosis during sick days.”
BackgroundMetabolic acidosis in patients with diabetes 2 undergoing cardiac surgery
Brekke, H. K., Holmaas, G., Astor, M. C., Steien, E., Haaverstad, R., Ghavidel, F. Z., & Farstad, M. (2024) · European Journal of Anaesthesiology · doi:10.1097/eja.0000000000002090 · Cited by 10
New Antihyperglycemic Drugs and Heart Failure: Synopsis of Basic and Clinical Data
von Lewinski, D., Kolesnik, E., Wallner, M., Resl, M., & Sourij, H. (2017) · BioMed Research International · doi:10.1155/2017/1253425 · Cited by 12
“Particularly ischemic and therefore endangered myocardium may benefit from these effects [83, 84].”
BackgroundMetformin Attenuates Myocardium Dicarbonyl Stress Induced by Chronic Hypertriglyceridemia
Malínská, H., Škop, V., Trnovská, J., Marková, I., Svoboda, P., Kazdová, L., & Haluzík, M. (2018) · Physiological Research · doi:10.33549/physiolres.933606 · Cited by 10
“…is perceived as a negative consequence associated with metformin administration (DeFronzo et al. 2016) recent trials with novel antidiabetic drugs gliflozins have suggested that moderate ketone bodies elevation could have the potential to improve myocardium metabolism (Ferrannini et al. 2016).”
BackgroundHuo, J.-Y., Jiang, W., Zhang, S., Lyu, Y.-T., Geng, J., Chen, M., Chen, Y., Jiang, Z., & Shan, Q. (2021) · Laboratory Investigation · doi:10.1038/s41374-021-00696-1 · Cited by 11
SGLT2 inhibitors: a new pillar of the heart failure regimen
DeSa, T. B., & Gong, T. (2021) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2204133 · Cited by 11
Garnica-Cuéllar, J. C., Lavalle-González, F. J., Magaña-Serrano, J. A., Almeda-Valdés, P., Canto, J. A. C., Chávez-Iñiguez, J. S., Garza-García, C. A., González-Chávez, A., González-Gálvez, G., Medina-Chávez, J. H., et al. (2022) · Gaceta Médica de México · doi:10.24875/gmm.m21000596 · Cited by 15
van Ruiten, C. C., Hesp, A. C., & van Raalte, D. H. (2022) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2022.03.031 · Cited by 11
Kugathasan, L., Sridhar, V. S., Lovblom, L. E., Matta, S., Saliba, A., Debnath, S., Alakwaa, F., Nair, V., Bjornstad, P., Kretzler, M., et al. (2023) · Diabetes · doi:10.2337/db23-0694 · Cited by 10
Poststatin era in atherosclerosis management: lessons from epidemiologic and genetic studies
Yvan‐Charvet, L., & Cariou, B. (2018) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000505 · Cited by 10
Seo, Y., Yamamoto, M., Machino‐Ohtsuka, T., Ishizu, T., & Aonuma, K. (2018) · Circulation Journal · doi:10.1253/circj.cj-18-0171 · Cited by 10
Ferrannini, G., & Rydén, L. (2018) · Clinical Science · doi:10.1042/cs20171374 · Cited by 10
Feng, X., Gu, Q., Gao, G., Yuan, L., Li, Q., & Zhang, Y. (2020) · Annales d Endocrinologie · doi:10.1016/j.ando.2020.07.1113 · Cited by 11
Botana, M., Escalada, J., Merchante, Á., Reyes‐García, R., & Rozas, P. (2022) · Diabetes Therapy · doi:10.1007/s13300-022-01277-1 · Cited by 11
Effects of glucose-lowering drugs on cardiovascular outcomes in patients with type 2 diabetes
Tomlinson, B., Hu, M., Zhang, Y., Chan, P., & Liu, Z.-M. (2016) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2016.1234608 · Cited by 10
A review of potential mechanisms and uses of SGLT2 inhibitors in ischemia-reperfusion phenomena
Quentin, V., Singh, M., & Nguyen, L. S. (2022) · World Journal of Diabetes · doi:10.4239/wjd.v13.i9.683 · Cited by 9
Kuo, H., Lai, Y., Lin, P., Chen, H.-H., Hung, C., Liu, L. Y., & Yeh, C.-K. (2023) · Scientific Reports · doi:10.1038/s41598-023-48716-y · Cited by 11
Ferrannini, E., Baldi, S., Frías, J. P., Guja, C., Hardy, E., Repetto, E., Jabbour, S. A., & DeFronzo, R. A. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13870 · Cited by 9
Self-citationRenal Effects of Sodium-Glucose Co-Transporter Inhibitors
Thomson, S. C., & Vallon, V. (2019) · The American Journal of Medicine · doi:10.1016/j.amjmed.2019.08.005 · Cited by 10
Does SGLT2 Inhibition Affect Sympathetic Nerve Activity in Type 2 Diabetes?
Dimova, R. B., & Tankova, T. I. (2020) · Hormone and Metabolic Research · doi:10.1055/a-1298-4205 · Cited by 12
Thirumathyam, R., Richter, E. A., Goetze, J. P., Fenger, M., van Hall, G., Dixen, U., Holst, J. J., Madsbad, S., Vejlstrup, N. G., Madsen, P. L., et al. (2022) · BMJ Open · doi:10.1136/bmjopen-2021-054100 · Cited by 10
Cardiac energy metabolism in heart failure
Lopaschuk, G. D., & Ho, K. L. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-99991-5.00002-4 · Cited by 9
Papaetis, G. S. (2024) · Archives of Medical Science - Atherosclerotic Diseases · doi:10.5114/amsad/176658 · Cited by 11
“…can act as super body fuel and enhance kidney oxygen efficiency by approximately 10%; (iii) suppression of protein-induced hyperfiltration and energy consumption by increasing glucagon levels; (iv) prevention of aberrant tubular glycolysis; and (v) modification of sympathetic activity [83–86].”
BackgroundThe Off-Target Cardioprotective Mechanisms of Sodium–Glucose Cotransporter 2 Inhibitors: An Overview
Ionică, L. N., Furdui-Lința, A. V., Bătrîn, A. D., Hâncu, I. M., Lolescu, B. M., Dănilă, M. D., Petrescu, L., Mozos, I. M., Sturza, A., & Muntean, D. M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25147711 · Cited by 10
Jürgens, M., Schou, M., Hasbak, P., Kjær, A., Wolsk, E., Zerahn, B., Wiberg, M., Brandt, N., Gæde, P., Rossing, P. R., et al. (2019) · BMJ Open · doi:10.1136/bmjopen-2019-029098 · Cited by 9
“23 However, others have shown that SGLT-2 inhibitors increase ATP production in mouse model hearts, without increasing ketone oxidation.”
BackgroundWang, S., Wu, T., Zuo, Z., Jin, P., Luo, X., & Deng, M. (2021) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwab099 · Cited by 9
Interaction between sodium-glucose co-transporter 2 and the sympathetic nervous system
Azzam, O., Matthews, V. B., & Schlaich, M. P. (2021) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000767 · Cited by 10
An evaluation of canagliflozin for the treatment of type 2 diabetes: an update
Minami, T., Kameda, A., & Terauchi, Y. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1939675 · Cited by 10
Insulin Resistance and Glucose Metabolism during Infection
Arneth, B. M. (2023) · Endocrines · doi:10.3390/endocrines4040049 · Cited by 8
Direct Cardiac Mechanisms of the Sodium Glucose Co-Transporter 2 Inhibitor Class
Hopkins, S. E., Baqai, F., Gajagowni, S., & Hickey, G. (2025) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/10742484251323428 · Cited by 9
“61 Almost all ATP generated by the healthy cardiomyocyte is through mitochondrial oxidation (95”
Suzuki, Y., & Amano, T. (2025) · Journal of Diabetes Investigation · doi:10.1111/jdi.70068 · Cited by 8
Cardiovascular Outcomes of New Medications for Type 2 Diabetes
Trujillo, J. M., Wettergreen, S. A., Nuffer, W. A., Ellis, S. L., & McDermott, M. T. (2016) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2016.0295 · Cited by 8
“40,41 This mechanism would work synergistically with increased oxygen release seen with SGLT-2 inhibition to improve myocardial contractility and cardiac efficiency, with possible dramatic effects in patients at risk for HF. 41 If true, this mechanism would open up new avenues for research and treatment of heart diseas…”
InfluentialWen, J., & Chen, C. (2023) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-023-10412-7 · Cited by 8
“Firstly, research has found that SGLT2i can increase the level of beta-hydroxybutyric acid in the blood while producing fewer ROS through its oxidation [97].”
Protective effect of empagliflozin against palmitate-induced lipotoxicity through AMPK in H9c2 cells
Song, M., Cui, W., Lee, C.-G., Cui, R., Son, Y. H., Kim, Y. H., Kim, Y., Kim, H. J., Choi, S., KANG, Y. Y., et al. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1228646 · Cited by 9
“The underlying mechanisms of these inhibitors in patients with or without T2D are not fully understood but are likely to involve multiple factors, including non-glycemic bene fi ts (Ferrannini et al., 2016; Kidokoro et al., 2019).”
Diabetes Care: “Taking It to the Limit One More Time”
Cefalu, W. T., Boulton, A. J. M., Tamborlane, W. V., Moses, R. G., LeRoith, D., Greene, E. L., Hu, F. B., Bakris, G. L., Wylie‐Rosett, J., Rosenstock, J., et al. (2017) · Diabetes Care · doi:10.2337/dc16-2326 · Cited by 8
Morillas, H., Galcerá, E., Alania-Torres, E., Seller, J., Larumbe, A., Núñez, J. E., & Valle, A. (2022) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2304139 · Cited by 9
“Hemoconcentra-tion subsequently promotes oxygen release to the tissues, thereby establishing a powerful synergy with the metabolic substrate shift [16].”
EMPA-REG OUTCOME: The Endocrinologist's Point of View
Perreault, L. (2017) · The American Journal of Medicine · doi:10.1016/j.amjmed.2017.04.005 · Cited by 9
Drug Development Strategy for Type 2 Diabetes: Targeting Positive Energy Balances
Liu, Z., & Yang, B. (2018) · Current Drug Targets · doi:10.2174/1389450120666181217111500 · Cited by 10
Monteiro, P. F., Aguíar, C., Matos, P., Silva‐Nunes, J., Birne, R., Branco, P. Q., Calado, J., Melo, M., & Polónia, J. J. (2019) · Revista Portuguesa de Cardiologia · doi:10.1016/j.repc.2019.02.008 · Cited by 13
Lioudaki, E., Joslin, J. R., Trachanatzi, E., & Androulakis, E. S. (2022) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2303082 · Cited by 10
Wu, Y., Tang, L., Zhang, F., Yan, Z., Li, J., & Tong, N. (2018) · International Journal of Endocrinology · doi:10.1155/2018/8457538 · Cited by 9
Ferrannini, E., Mark, M., & Mayoux, E. (2016) · Diabetes Care · doi:10.2337/dci16-0033 · Cited by 8
Self-citationCardiac Involvement in Diabetes
Galderisi, M., Esposito, R., & Trimarco, B. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.08.039 · Cited by 8
Sodium‐Glucose Cotransporter 2 Inhibitors Use in Patients With Liver Cirrhosis
Yen, F., Hou, M., Wei, J. C., Huang, Y., Shih, Y., Pan, C., Wang, S.-T., Hwu, C., & Hsu, C. (2025) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.70070 · Cited by 7
“They may offer protective effects on cirrhotic hepatocytes with hypoxic status and attenuate the persistent injury of hepatic tissue [7, 23, 24].”
Current treatment for diabetes: a holistic approach
Mourelatou, N. G., Kounatidis, D. C., Vallianou, N. G., Daniele, G., Dardano, A., & Rebelos, E. (2025) · HORMONES · doi:10.1007/s42000-025-00734-3 · Cited by 8
“These findings were particularly notable, as prior studies had failed to show any CV benefit from glu - cose-lowering drugs in patients with HF [74, 75].”
Beneficial cardiovascular and remodeling effects of SGLT 2 inhibitors
Chrysant, S. G., & Chrysant, G. S. (2022) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2022.2057949 · Cited by 8
Khayari, A. E., Hakam, S. M., Malka, G., Rochette, L., & Fatimy, R. E. (2023) · Genes & Diseases · doi:10.1016/j.gendis.2023.101174 · Cited by 8
“54 In the heart, SGLT2is modulate the glucocentric metabolism in the failed heart and restore more efficient fuel energetics with increased oxidation of ketone bodies and branched-chain amino acids.”
BackgroundSelvaraj, S., Kwee, L. C., Thompson, E. J., He, M., Hornik, C. P. V., DeVore, A. D., Patel, C. B., Mentz, R. J., Fudim, M., Taylor, L., et al. (2024) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2024.10.014 · Cited by 8
Crabtree, C. D., Stoner, J., Buga, A., Robinson, B., Decker, D. D., Chebbi, A., El‐Shazly, X., Murphy, E., Jordan, A., Bedell, T., et al. (2025) · Physiological Reports · doi:10.14814/phy2.70397 · Cited by 7
“…at a potential energetic efficiency mechanism (Evans et al., 2017) that has been previously theorized generally (Cox & Clarke, 2014; Veech, 2004) and in the cardiovascular context of myocardial ex-ternal efficiency (MEE), relevant to aerobic exercise performance (Ferrannini, Mark, & Mayoux, 2016).”
Dapagliflozin for the treatment of type 1 diabetes mellitus
Pafili, K., Maltezos, E. S., & Παπάνας, Ν. (2017) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2017.1339788 · Cited by 7
Bauduceau, B., Bordier, L., Bringer, J., Chabrier, G., Charbonnel, B. H., Cosson, E., Darmon, P., Detournay, B., Fontaine, P., Gourdy, P., et al. (2019) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(19)30056-2 · Cited by 20
Lim, S. K. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13696 · Cited by 9
“Glucagon release by pancreatic α-cells is increased following SGLT2 inhibition, which might be beneficial in heart failure through its ionotropic effects,(26) but also by increasing the availability of circulating ketones, thereby providing organs that are critically challenged by hypoxia with an advantageous energy s…”
BackgroundFerrari, F., Martins, V. M., Scheffel, R. S., da Silveira, A. D., Motta, M. T., Moriguchi, E. H., Santos, R. D., & Stein, R. (2021) · Annals of Pharmacotherapy · doi:10.1177/1060028020985111 · Cited by 9
Sodium-Glucose Cotransporter Inhibitors in Non- Diabetic Heart Failure: A Narrative Review
Dahal, R. K., Acharya, Y., & Mukherjee, D. (2021) · Cardiovascular & Haematological Disorders - Drug Targets · doi:10.2174/1871529x20999201231205504 · Cited by 7
Galli, M., D’Amario, D., Sofia, C., Vaccarella, M., Crea, F., & Aspromonte, N. (2018) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2018.1551360 · Cited by 8
Shah, S. R., Iqbal, S. M., Alweis, R. L., & Roark, S. F. (2018) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2019.1552830 · Cited by 7
Nashawi, M., Sheikh, O., Battisha, A., Mir, M., & CHILTON, R. J. (2020) · Heart Failure Reviews · doi:10.1007/s10741-020-09996-y · Cited by 7
de Kreutzenberg, S. V., & Avogaro, A. (2017) · Journal of Endocrinological Investigation · doi:10.1007/s40618-017-0615-0 · Cited by 10
EMPA-REG OUTCOME: The Endocrinologist's Point of View
Perreault, L. (2017) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2017.05.010 · Cited by 8
Maranta, F., Cianfanelli, L., Regoni, M., & Cianflone, D. (2018) · IJC Heart & Vasculature · doi:10.1016/j.ijcha.2018.10.001 · Cited by 7
Advances in reducing cardiovascular risk in the management of patients with type 2 diabetes mellitus
Hu, Y. (2019) · Chronic Diseases and Translational Medicine · doi:10.1016/j.cdtm.2019.01.001 · Cited by 7
Anomalies de la β-oxydation mitochondriale des acides gras: Maladies rares et maladies communes
Bastin, J., & Djouadi, F. (2019) · médecine/sciences · doi:10.1051/medsci/2019156 · Cited by 10
Metabolomics Insights into the Benefits of SGLT2 Inhibitors in Type 2 Diabetes
Kyriakidou, A., Koufakis, T., Gika, H., & Kotsa, K. (2025) · Clinical Pharmacology Advances and Applications · doi:10.2147/cpaa.s497906 · Cited by 13
Cardiac substrate metabolism in type 2 diabetes
Chan, J. S. F., Shafaati, T., & Ussher, J. R. (2025) · Biochemical Journal · doi:10.1042/bcj20240189 · Cited by 9
“The sodium-glucose cotransporter-2 (SGLT2) inhibitors are another drug class for T2D that have also been shown to improve cardiovascular outcomes [132], and a popular hypothesis to explain their cardioprotective actions stems from their ability to increase circulating ketones [23,133].”
Ibrahim, M. O., Mohamed, O. M., & Ali, N. M. (2025) · Cureus · doi:10.7759/cureus.90684 · Cited by 7
“Additionally, they improve myocardial energetics through enhanced ketone body metabolism, reduce myocardial fibrosis and inflammation, protect renal function, and potentially modulate neurohormonal activity, all of which are relevant to HF pathophysiology regardless of glycemic status [14,15].”
Sharma, A., Baig, S. A., Thayakaran, R., Rengarajan, L. N., Philip, N. C., Abraham, A. A., Manta, A., Narendran, P., Dhatariya, K., Umpierrez, G. E., et al. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70098 · Cited by 7
“27 This metabolic shift may exacerbate ketogenesis and acidosis even in the absence of severe hyperglycaemia.”
Sato, J., Kinoshita, K., & Sakurai, A. (2023) · Open Medicine · doi:10.1515/med-2023-0793 · Cited by 6
Thirumathyam, R., Richter, E. A., van Hall, G., Holst, J. J., Fenger, M., Goetze, J. P., Dixen, U., Vejlstrup, N. G., Madsbad, S., Madsen, P. L., et al. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-023-02094-x · Cited by 6
“Based on data from a previous study using the same Cardiac MRI protocol to determine cardiac function in young elderly healthy subjects [4], we assumed that T2DM patients had LVPFR corresponding to healthy elderly subjects and that empagliflozin treatment would improve LVPFR by 30 ml/s compared to…”
BackgroundMethodXia, W., Zhang, M., Liu, C., Wang, S., Xu, A., Xia, Z., Pang, L., & Cai, Y. (2024) · Life Sciences · doi:10.1016/j.lfs.2024.122594 · Cited by 6
Protective Mechanisms of SGLTi in Ischemic Heart Disease
Liao, L., Wang, T., Zhang, L., Yan, W., & Fan, X. (2024) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-024-10513-x · Cited by 6
“KB is a valuable substrate for energy production (lower oxygen demand and higher ATP production) and significantly improve cardiac efficiency [26, 30].”
Elliott, J., & Oyama, M. A. (2024) · Journal of Veterinary Pharmacology and Therapeutics · doi:10.1111/jvp.13472 · Cited by 8
Ryder, R. E. J., & DeFronzo, R. A. (2016) · British Journal of Diabetes · doi:10.15277/bjd.2016.096 · Cited by 7
Yanagawa, T. (2017) · Journal of Clinical Medicine Research · doi:10.14740/jocmr3014w · Cited by 7
SGLT2 Inhibitors: Rationale and Perspectives of Use in Heart Failure
Kobalava, Z. D., Lazarev, P. V., & Вадимовна, В. С. (2018) · Kardiologiia · doi:10.18087/cardio.2018.2.10087 · Cited by 7
Adji, A. S., Billah, A., Baraja, A., Putri, A. A. P., & Rahman, F. S. (2022) · Open Access Macedonian Journal of Medical Sciences · doi:10.3889/oamjms.2022.8017 · Cited by 6
Effects of dapagliflozin on postprandial lipid metabolism in type 2 diabetes mellitus
Burggraaf, B., Pouw, N. M. C., Fernández‐Arroyo, S., der Zee, L. C. V. V.-V., van de Geijn, G.-J. M., Birnie, E., Huisbrink, J., van der Zwan, E. M., de Herder, W. W., Mulder, M. T., et al. (2022) · European Journal of Endocrinology · doi:10.1530/eje-21-1270 · Cited by 6
New insights and advances of sodium-glucose cotransporter 2 inhibitors in heart failure
Li, J., Zhou, L., & Gong, H. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.903902 · Cited by 6
Wang, S., Neumann, D., Westenbrink, B. D., Schianchi, F., Wong, L.-Y., Sun, A., Strzelecka‐Kiliszek, A., Glatz, J. F. C., Luiken, J. J. F. P., & Nabben, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232112909 · Cited by 7
Oral, E. A. (2016) · Drugs in Context · doi:10.7573/dic.212299 · Cited by 6
Strojek, K., Rokicka, D., Szymborska‐Kajanek, A., & Wróbel, M. P. (2016) · Clinical Diabetology · doi:10.5603/dk.2016.0018 · Cited by 6
Cardiovascular Outcomes Trials of Glucose-Lowering Drugs or Strategies in Type 2 Diabetes
Gerstein, H. C., & Shah, R. (2017) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2017.10.003 · Cited by 6
Lambadiari, V., Dimitriadis, G., & Kadoglou, N. P. E. (2018) · Heart Failure Reviews · doi:10.1007/s10741-018-9690-3 · Cited by 6
An evaluation of the efficacy and safety of Tofogliflozin for the treatment of type II diabetes
Aharon‐Hananel, G., & Raz, I. (2019) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2019.1583210 · Cited by 6
Kobayashi, K., Toyoda, M., Kaneyama, N., Hatori, N., Furuki, T., Sakai, H., Takihata, M., Umezono, T., Ito, S., Suzuki, D., et al. (2019) · Journal of Diabetes Research · doi:10.1155/2019/9415313 · Cited by 6
Pharmacotherapeutic principles of fluid management in heart failure
Narasimhan, B., Aravinthkumar, R., Correa, A. A., & Aronow, W. S. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2020.1850694 · Cited by 7
Jensen, J., Omar, M., Ali, M., Frederiksen, P. H., Kistorp, C., Tuxen, C., Andersen, C. F., Larsen, J. H., Ersbøll, M. K., Køber, L., et al. (2022) · American Heart Journal · doi:10.1016/j.ahj.2022.04.008 · Cited by 6
Kosiborod, M., Cavender, M. A., Fu, A. Z., Wilding, J. P. H., Khunti, K., Holl, R. W., Norhammar, A., Birkeland, K. I., Jørgensen, M. E., Thuresson, M., et al. (2018) · Circulation · doi:10.1161/circulationaha.117.031847 · Cited by 6
Perissiou, M., SAYNOR, Z. L., Feka, K., Edwards, C., James, T. J., Corbett, J., Mayes, H. S., Shute, J. K., Cummings, M., Black, M. I., et al. (2025) · Journal of Applied Physiology · doi:10.1152/japplphysiol.00800.2024 · Cited by 5
Ketone Bodies in Cardiovascular Disease
Challa, A. A., Hill, B. G., Nystoriak, M. A., Gouwens, K. R., & Kalra, D. K. (2025) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2025.101328 · Cited by 6
Li, A., Wang, X., Yang, R., Zhang, J., & Jiang, X. (2025) · Chinese Herbal Medicines · doi:10.1016/j.chmed.2025.07.002 · Cited by 5
“Therefore, ketone bodies serve as a viable energy source to maintain cardiac efficiency during hypoxia and heightened energy requirements (Ferrannini, Mark, & Mayoux, 2016).”
Carrera‐Bastos, P., Muskiet, M. H. A., Ordóñez, F. M., Pruimboom, L., Lucía, A., Luque, R. M., & Muskiet, F. A. J. (2025) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-025-09996-z · Cited by 8
Favorable outcomes of SGLT2 inhibitor use in pacemaker recipients: a population-based study
Avidan, Y., Danon, A., Hadar, D., Aker, A., Yahav, A., Caspi, O., & Kassem, S. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02992-2 · Cited by 5
“Notably, HF prompts a metabolic switch in the myocardium—from fatty acid oxidation to glucose utilization—which lowers oxygen demand but simultaneously restricts adenosine triphosphate production [39–41].”
Kim, C.-W., do Vale, G. D., Fu, X., McDonald, J. G., Dai, C., Li, C., Wang, Z. V., Sharma, G., Khemtong, C., Malloy, C. R., et al. (2026) · Journal of Clinical Investigation · doi:10.1172/jci202528 · Cited by 6
“…advanced stages of heart failure has been proposed to limit oxygen consumption and oxidative stress and thereby confer functional protection (61, 80–82), an actively regulated metabolic switch is unlikely to account for the late-stage decline in ACC dHKO hearts because malonyl-CoA–mediated control…”
Svart, M. V., Nielsen, M. M., Rittig, N. F., Hansen, M., Møller, N., & Gravholt, C. H. (2023) · Scandinavian Journal of Medicine and Science in Sports · doi:10.1111/sms.14441 · Cited by 5
Bae, J. H., Kim, Y.-E., Jung, K. J., Jee, S. H., & Lee, B. (2025) · Nutrition and Diabetes · doi:10.1038/s41387-025-00364-z · Cited by 6
Metabolomics Profiling of Epicardial Adipose Tissue: MESA and the Rotterdam Study
Neeland, I. J., Zhu, F., Graça, G., Lymperopoulos, A., Iacobellis, G., Farzaneh, A., Bos, D., Ghanbari, M., Goldberger, J. J., Kavousi, M., et al. (2025) · Journal of the American Heart Association · doi:10.1161/jaha.124.039750 · Cited by 7
“38 EAT can therefore serve as mediator for the use of lipid-derived energy.”
Diabetologie als fächerübergreifende interdisziplinäre Herausforderung
Müller‐Wieland, D., & Marx, N. (2017) · Der Internist · doi:10.1007/s00108-017-0204-5 · Cited by 5
Sasaki, Y., Koyano, K., Iida, S., & Yanagawa, T. (2017) · Journal of Diabetes Mellitus · doi:10.4236/jdm.2017.74019 · Cited by 5
Dalan, R. (2018) · Cardiology in Review · doi:10.1097/crd.0000000000000201 · Cited by 6
Metadata
- Authors
- Ferrannini, E., Mark, M., & Mayoux, E.
- Affiliations
- Istituto di Fisiologia Clinica (IT)
- Boehringer Ingelheim (Germany) (DE)
- Corresponding author
- Ferrannini, Ele
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2016-06-11
- Volume
- 39
- Issue
- 7
- Pages
- 1108-1114
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2412800896
- Cited by
- 975
- References
- 77
- Citations by year
- 2026: 53 · 2025: 53 · 2024: 73 · 2023: 79 · 2022: 91 · 2021: 134 · 2020: 114 · 2019: 100 · 2018: 110 · 2017: 119 · 2016: 47
- FWCI
- 125.98
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Keywords
- SGLT2 inhibitors, EMPA-REG OUTCOME trial, cardioprotection, type 2 diabetes, hyperketonemia, beta-hydroxybutyrate, mitochondrial oxygen consumption, hemoconcentration, heart failure, cardiovascular mortality, diabetic heart disease
- MeSH terms
- Sodium-Glucose Transporter 2 Inhibitors, Benzhydryl Compounds, Blood Glucose, Blood Pressure, Cardiovascular Diseases, Clinical Trials as Topic, Diabetes Mellitus, Type 2, Diabetic Angiopathies, Glucosides, Heart, Humans, Hypoglycemic Agents, Models, Biological, Research Design, Treatment Outcome, 3-Hydroxybutyric Acid, Sodium-Glucose Transporter 2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.